{"id":"imidafenacin","rwe":[{"pmid":"41161786","year":"2025","title":"Evaluation of the Potential Inhibitory Effects of Medications for Detrusor Overactivity on Platelet-Activating Factor (PAF)-Induced Mechanical Activity in Guinea Pig Bladder Smooth Muscle.","finding":"","journal":"Biological & pharmaceutical bulletin","studyType":"Clinical Study"},{"pmid":"40543999","year":"2025","title":"Additive effects of mirabegron on muscarinic receptor binding and on relaxation of cholinergic detrusor muscle contraction by antimuscarinics.","finding":"","journal":"Journal of pharmacological sciences","studyType":"Clinical Study"},{"pmid":"40409571","year":"2025","title":"Development of long-acting imidafenacin transdermal patches with high drug loading based on solid dispersion technology.","finding":"","journal":"International journal of pharmaceutics","studyType":"Clinical Study"},{"pmid":"39343691","year":"2025","title":"Mirabegron Versus Placebo and Other Therapeutic Modalities in the Treatment of Patients with Overactive Bladder Syndrome-A Systematic Review.","finding":"","journal":"European urology focus","studyType":"Clinical Study"},{"pmid":"39249919","year":"2024","title":"Efficacy and safety evaluation of imidafenacin administered twice daily for continency recovery following radical prostatectomy in prostate cancer patients: Prospective open-label case-controlled randomized trial.","finding":"","journal":"Investigative and clinical urology","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Muscarinic acetylcholine receptor M3","category":"target"},{"label":"CHRM3","category":"gene"},{"label":"CHRM1","category":"gene"},{"label":"G04BD14","category":"atc"},{"label":"Active","category":"status"},{"label":"Bladder muscle dysfunction - overactive","category":"indication"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=IMIDAFENACIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:37:47.399220+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:37:52.700563+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IMIDAFENACIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:37:53.116303+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Muscarinic acetylcholine receptor M3 antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:37:54.168023+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL53366/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:37:53.821384+00:00"}},"allNames":"uritos","offLabel":[],"synonyms":["imidafenacin","uritos","KRP-197","KRP 197"],"timeline":[{"date":"2007-04-18","type":"positive","source":"DrugCentral","milestone":"PMDA approval"}],"approvals":[{"date":"2007-04-18","orphan":false,"company":"","regulator":"PMDA"}],"brandName":"Uritos","ecosystem":[{"indication":"Bladder muscle dysfunction - overactive","otherDrugs":[{"name":"butacaine","slug":"butacaine","company":""},{"name":"darifenacin","slug":"darifenacin","company":"Warner Chilcott Llc"},{"name":"fesoterodine","slug":"fesoterodine","company":"Pfizer"},{"name":"mirabegron","slug":"mirabegron","company":"Apgdi"}],"globalPrevalence":null}],"mechanism":{"target":"Muscarinic acetylcholine receptor M3","targets":[{"gene":"CHRM3","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M3","protein":"Muscarinic acetylcholine receptor M3"},{"gene":"CHRM1","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M1","protein":"Muscarinic acetylcholine receptor M1"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Uritos (Imidafenacin) is a selective M3 muscarinic receptor antagonist, which means it specifically blocks the action of acetylcholine at the M3 receptor, leading to relaxation of the bladder muscle and decreased bladder contractions."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4902","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=IMIDAFENACIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IMIDAFENACIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:01:36.582654","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:37:55.629574+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"flavoxate","drugSlug":"flavoxate","fdaApproval":"1970-01-15","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"oxybutynin","drugSlug":"oxybutynin","fdaApproval":"1975-07-16","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tolterodine","drugSlug":"tolterodine","fdaApproval":"1998-03-25","genericCount":15,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"solifenacin","drugSlug":"solifenacin","fdaApproval":"2004-11-19","patentExpiry":"May 18, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"trospium","drugSlug":"trospium","fdaApproval":"2004-05-28","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"darifenacin","drugSlug":"darifenacin","fdaApproval":"2004-12-22","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fesoterodine","drugSlug":"fesoterodine","fdaApproval":"2008-10-31","patentExpiry":"Jun 7, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"mirabegron","drugSlug":"mirabegron","fdaApproval":"2012-06-28","patentExpiry":"Sep 30, 2036","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"imidafenacin","indications":{"approved":[{"name":"Bladder muscle dysfunction - overactive","source":"DrugCentral","snomedId":236633002,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"flavoxate","brandName":"flavoxate","genericName":"flavoxate","approvalYear":"1970","relationship":"same-class"},{"drugId":"oxybutynin","brandName":"oxybutynin","genericName":"oxybutynin","approvalYear":"1975","relationship":"same-class"},{"drugId":"tolterodine","brandName":"tolterodine","genericName":"tolterodine","approvalYear":"1998","relationship":"same-class"},{"drugId":"solifenacin","brandName":"solifenacin","genericName":"solifenacin","approvalYear":"2004","relationship":"same-class"},{"drugId":"trospium","brandName":"trospium","genericName":"trospium","approvalYear":"2004","relationship":"same-class"},{"drugId":"darifenacin","brandName":"darifenacin","genericName":"darifenacin","approvalYear":"2004","relationship":"same-class"},{"drugId":"fesoterodine","brandName":"fesoterodine","genericName":"fesoterodine","approvalYear":"2008","relationship":"same-class"},{"drugId":"mirabegron","brandName":"mirabegron","genericName":"mirabegron","approvalYear":"2012","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02294396","phase":"PHASE4","title":"Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-10-28","conditions":["Overactive Bladder (OAB)"],"enrollment":649,"completionDate":"2016-09-07"},{"nctId":"NCT03602508","phase":"","title":"Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania","status":"COMPLETED","sponsor":"Astellas Pharma Singapore Pte. Ltd.","startDate":"2018-07-20","conditions":["Overactive Bladder (OAB)"],"enrollment":5589,"completionDate":"2019-09-13"},{"nctId":"NCT03572231","phase":"","title":"A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China","status":"COMPLETED","sponsor":"Astellas Pharma Singapore Pte. Ltd.","startDate":"2018-07-19","conditions":["Overactive Bladder (OAB)"],"enrollment":805,"completionDate":"2020-03-30"},{"nctId":"NCT03575702","phase":"PHASE3","title":"Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2016-07-18","conditions":["Overactive Bladder"],"enrollment":300,"completionDate":"2017-09-01"},{"nctId":"NCT00212706","phase":"PHASE2","title":"Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2001-10","conditions":["Overactive Bladder"],"enrollment":400,"completionDate":""},{"nctId":"NCT00212732","phase":"PHASE3","title":"Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2003-10","conditions":["Overactive Bladder"],"enrollment":750,"completionDate":""},{"nctId":"NCT00512785","phase":"PHASE3","title":"Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2007-08","conditions":["Overactive Bladder"],"enrollment":435,"completionDate":""},{"nctId":"NCT01578304","phase":"PHASE4","title":"Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2010-12","conditions":["Overactive Bladder"],"enrollment":207,"completionDate":"2011-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"XJR8Y07LJO","CHEBI":"CHEBI:134720","INN_ID":"8402","UMLSCUI":"C1876226","chemblId":"CHEMBL53366","ChEMBL_ID":"CHEMBL53366","KEGG_DRUG":"D06273","DRUGBANK_ID":"DB09262","PUBCHEM_CID":"6433090","MESH_SUPPLEMENTAL_RECORD_UI":"C120953"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"3.2 hours","clearance":"6.1 mL/min/kg","bioavailability":"58%","fractionUnbound":"0.12%","volumeOfDistribution":"1.51 L/kg"},"publicationCount":110,"therapeuticAreas":["Urology"],"atcClassification":{"source":"DrugCentral","atcCode":"G04BD14","allCodes":["G04BD14"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025","pmid":"41161786","title":"Evaluation of the Potential Inhibitory Effects of Medications for Detrusor Overactivity on Platelet-Activating Factor (PAF)-Induced Mechanical Activity in Guinea Pig Bladder Smooth Muscle.","journal":"Biological & pharmaceutical bulletin"},{"date":"2025 Aug","pmid":"40543999","title":"Additive effects of mirabegron on muscarinic receptor binding and on relaxation of cholinergic detrusor muscle contraction by antimuscarinics.","journal":"Journal of pharmacological sciences"},{"date":"2025 Jun 30","pmid":"40409571","title":"Development of long-acting imidafenacin transdermal patches with high drug loading based on solid dispersion technology.","journal":"International journal of pharmaceutics"},{"date":"2025 Mar","pmid":"39343691","title":"Mirabegron Versus Placebo and Other Therapeutic Modalities in the Treatment of Patients with Overactive Bladder Syndrome-A Systematic Review.","journal":"European urology focus"},{"date":"2024 Sep","pmid":"39249919","title":"Efficacy and safety evaluation of imidafenacin administered twice daily for continency recovery following radical prostatectomy in prostate cancer patients: Prospective open-label case-controlled randomized trial.","journal":"Investigative and clinical urology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Uritos is a small molecule that acts as a muscarinic acetylcholine receptor M3 antagonist. It is used to treat overactive bladder, as indicated by clinical trials comparing its efficacy and safety to Urotol.","enrichmentLevel":3,"visitCount":5,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2007-04-18T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:37:55.629574+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}